Phyto-Cannabinoids
for Women’s Health
About US
FEMESTRO aims to develop innovative phytocannabinoid-based therapies for women’s health
A deep understanding of the cannabinoid pathway enables a novel approach supporting women’s health
Led by a team of experienced professionals in pharmaceuticals development
OUR MISSION
Femestro is pioneering new avenues in women’s health, addressing significant unmet needs in hormone-related diseases and other chronic conditions using innovative phyto-cannabinoids that are potentially safer treatments
OUR SCIENCE
Health
Challenges
Women face unique health issues, including hormone-driven cancers, menstrual migraines, and chronic conditions like endometriosis
Novel
Solutions
Phyto-cannabinoids are naturally occurring compounds from cannabis are being explored for their therapeutic potential, especially in hormone-related health challenges
Novel
MoA
Cannabinoids can be tailored to target specific pathways involved in female-specific health conditions
Lowering
side effects
Phyto-cannabinoids, unlike synthetic hormones, offer potential therapeutic benefits with fewer side effects
Pipeline
Proprietary phyto-cannabinoids and their analogues
are being developed for multiple women’s health indications
Our Capabilities
FEMESTRO is equipped with R&D infrastructure that focuses on developing cutting-edge cannabinoid-based therapies
The company’s R&D team comprises experts in pharmacology, molecular biology, and biochemistry, dedicated to advancing novel phyto-cannabinoids
The capabilities include state-of-the-art laboratory facilities, advanced in vitro and in vivo modeling, and strong expertise in the analysis of cannabinoids
OUR TEAM
Shmuel (Muli) Mandel, PhD
15 years of experience leading medical companies, Former VP Marketing & BD at DNR Bio Imagine, CEO & VP Marketing at AptaTeck Bio, VP of M&S at Rhenium, PhD in biochemistry and neuroscience
Prof. David (Dedi) Meiri, PhD
Leading KOL in cannabis research, head of the Cancer Biology and Cannabinoid Research Lab, Technion, heads up Cannabis DB project, MSc in biochemistry. PhD in plant biology, Post doc at Ontario Cancer Institute
Shmuel Tuvia, PhD
Senior biopharmaceutical executive with >25-years experience. Formerly, CSO at Ayala Pharm (NASDAQ:ADXS), CDO at Ukko, COO at Eloxx (NASDAQ:ELOX), VP Preclinical at Chiasma Pharmaceuticals (NASDAQ: CHMA) and more
Rotem Perry Feigenbaum, PhD
Extensive experience in analytical research. Over 10 years of R&D expertise. Former head of analytica dpt. at Virdia. PhD in organic chemistry
Dori Pelled, PhD
Extensive experience in analytical research. Over 10 years of R&D expertise. Former head of analytica dpt. at Virdia. PhD in organic chemistry
